| Purpose：Tumor is one of the world’s leading cause of death, our annual newcases of malignant tumor in1600000, death1300000, existing in about2000000of the patients, the tumor to the family and the society brought heavy disasterand to estimate human, material and financial resources, huge losses.TraditionalChinese medicine in the prevention and treatment of radiotherapy andchemotherapy, toxicity, improve immunity, prevent tumor recurrence, improve thequality of life, survival and so has a unique advantage. We apply the ChinaAcademy of traditional Chinese medicine research group of "traditional Chinesemedicine auxiliary transmission system", established Chinese medicine tumorauxiliary heritage database, in the database into the traditional Chinesemedicine aided tumor radiotherapy and chemotherapy,97effective prescription,using the system analysis software to obtain a new prescription.On the basisof many years of clinical experience summary of tutor with side consisting ofAetna oral liquid A and B prescription prescription. In the A recipe experimentalstudy, has proven its on tumor-bearing mice with tumor and prolong the survivaltime of the role. The experimental study of A Aetna oral liquid prescriptionand B herbs on tumor bearing mice increased white blood cells and immuneregulation effects, in order to get the best prescription of Aetna oral liquidmedicine.Material and method：1Material: healthy Kunming mice, male and female half, weight18-22g.Cyclophosphamide, heparin sodium injection, India ink,722spectrophotometer,BC3000full automatic blood cell analyzer, MODEL DS-671models of electronicscales, drug: Aetna oral liquid in A group: psoralen Coix Astragalus AtractylodesPinellia orange tuckahoe, B group: Astragalus Ligustrum lucidum diffusaCodonopsis etc.2Method: 2.1Model: will have been vaccinated7days good ascites tumor growth in micesuction milky white thick ascites, and saline by1:3ratio of dilution, and bloodcount plate counts of tumor cell, adjust the cell count was1×107/ml, made ofa tumor cell suspension. Tumor cell vaccination before, with0.2%trypan bluestaining, count living cell rate>95%. In the mouse right anterior subcutaneousinjection of0.2mlS180cell suspension (approximately2×106cells), made of solidtumor model.2.2Animal animal groups were randomly divided into4groups, each group of10,male and female half and half. Respectively: control group, model group, A group,B group. In addition to the control group, the remaining3groups are alltumor-bearing mouse S180.2.3Animal drug：A group gives the tumor-bearing mice Aprescription0.4ml/only/day (containing2.85g/ml) B group was given Bprescription0.4ml/only/day (containing1.45g/ml) by gavage, control group,model group were given normal saline0.4ml gavage.2.4Aetna oral liquid increasing leukocyte effect experiment: except for thecontrol group, the remaining3group (A group, B group, model group) oftumor-bearing mice were intraperitoneal injection of cyclophosphamide inducedbone marrow suppression model, each tumor-bearing mice peritoneal injection of0.2ml,100mg/kg, for3consecutive days caused leukopenia model, tenth days24hours after dosing end, removal of tumor-bearing mice eye blood specimenacquisition, detection of peripheral blood white cell count.2.5The mononuclear phagocytic experiment: consecutive gavage for10days. Afterthe last administration according to the24h,10m1/kg tail vein injection ofdiluted India ink,2min and10min respectively from the eye blood20ul, dissolvedin a solution of2ml0.1%Na2CO3strain, the type722spectrophotometerdetermination of600nm wavelength absorbance(OD) value. Record weight of mice,mice cervical dislocation were sacrificed, weighing spleen, liver weight,calculation of clearance index K and phagocytosis index alpha,K=(LogOD1-logOD2)/(T2-t1), the phagocytic index alpha=K1/3×body weight/(liver and spleen).2.6Delayed hypersensitivity (DTH) experiment: except for the control group,the remaining3group (Agroup, Bgroup, model group) of tumor-bearing mice usingplantar thickening method, namely to mice by intraperitoneal injection of2%(V/V)SRBC,0.2mL/rat (approximately1×108SRBC) sensitized4D, left footpadthickness measurement, and then in the measurement of hypodermic injection siteof20%(V/V)SRBC,20ul/rat (approximately1×108SRBC) to24h after injectionmeasurement of left foot plantar thickness, the same site were measured3times,and the average value. To attack before and after footpad thickness difference(pawswelling) representing the DTH degree.Results:1Aetna oral liquid from an elevated white blood cell effect visible: medicationtenth days after the controls the differential white blood cell count was7.6+0.6,Aetna oral liquid in A group differential white blood cell count was5.1+0.3,5.9+0.5B group, model group differential white blood cell count is2.9+0.6. Compared with the model group, Aetna oral liquid in A group and B groupof white blood cell count were significantly different (P<0.01); B group andA group had significant difference (P<0.01).2From the mononuclear phagocytic experiment shows: after administration,control group clearance index difference is0.131+0.042,5.48+0.54phagocyticcoefficient difference; Aetna oral liquid in A group clearance index differenceis0.226+0.780,6.10+0.67phagocytic coefficient difference; Aetna oral liquidin B group author index difference is0.134+0.042,5.65+0.65phagocyticcoefficient difference; Aetna oral liquid in A group and B group and model group,blank control group there were significant differences (P<0.05); A group andB group compared with the model group can increase the clearance index andtumor-bearing mice phagocytic coefficients; A group and B group comparison,clearance index have significant difference (P<0.05).3From the delayed hypersensitivity (DTH) experimental visible: after administration of contrast group paw thickness deviation of0.03+/-0.01; A grouppaw thickness deviation of0.33+/-0.07; B group paw thickness deviation of0.34+/-0.28; Aetna oral liquid in A group and B group and control group, comparedwith model group, with significant difference (P<0.05). A group and B group hasno significant difference (P>0.05).Conclusion:1Aetna oral liquid by increasing leukocyte effect experiment of visible, Aetnaoral liquid in A group and B group can improve the tumor-bearing mice due toinjection of cyclophosphamide induced bone marrow suppression and reduce thenumber of leukocytes, owing Aetna oral liquid in A group and B group group, inimproving the tumor-bearing mice leukocytes different roles. A group and B groupcompared with B group, can significantly improve the tumor-bearing mice bonemarrow suppression and reduced the number of white blood cells.2Aetna oral liquid by mononuclear phagocytic experiment result, Aetna oralliquid in A group and B group can be improved from tumor-bearing S180mice resultedin immunocompromised mice, increase the carbon clearance index and phagocyticcoefficients, and delayed allergy in tumor-bearing mice left hind foot plantarthickness difference increases. But the A group and B group, A groupsignificantly increase the carbon clearance index and phagocytic coefficients,visible A side group can be significantly improved by the tumor-bearing miceinduced by S180low immune function. |
PDF Full Text Request